Qiagen buys 61% of Ipsogen, beefs up its Cellestis offer

July 2011
Medical Device Daily;7/12/2011, Vol. 15 Issue 128, p2
The article reports on the acquisition by Qiagen of 61% of Ipsogen, a developer of molecular profiling and personalized healthcare diagnostics for a wide range of applications in the hematology field.


Related Articles

  • Qiagen offers $101 million for 47% stake in Ipsogen.  // Medical Device Daily;6/17/2011, Vol. 15 Issue 112, p2 

    The article focuses on the plan of Qiagen to acquire a 47% stake in Ipsogen. The acquisition deal, valued at 101 million U.S. dollars, would provide Qiagen access to wide range of assays covering several biomakers. According to Peer Schatz of Qiagen, the deal would further expand the company's...

  • Qiagen completes Digene buy; ME buys stroke treatment rights.  // Medical Device Daily;8/1/2007, Vol. 11 Issue 145, p2 

    The article reports on the completion of the acquisition of Digene by Qiagen of the Netherlands. Report says that Qiagen has completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of the company. Under the deal, Digene will become...

  • Qiagen's shareholders okay $1.6 billion merger with Digene.  // Medical Device Daily;7/23/2007, Vol. 11, p6 

    The article announced that Qiagen has received the vote of the necessary percentage of its shareholders in favor of the $1.6 billion acquisition of Digene at its extraordinary general meeting of shareholders held in the Netherlands. The companies reported that they had entered into a merger...

  • Rapigene bargain buy for Qiagen. Hodgson, John // Nature Biotechnology;Feb2000, Vol. 18 Issue 2, p132 

    Reports on the acquisition of the genomic analysis company Rapigene by the biotechnology company Qiagen NV. Factors which led to the acquisition of the genomic analysis company; Owner of Rapigene prior to the acquisition.

  • Qiagen now boasting extra Ingenuity after acquisition.  // Scientific Computing World;Jun/Jul2013, Issue 130, p4 

    The article reports on the acquisition of U.S.-based Ingenuity Systems Inc., provider of software solutions, by Qiagen NV, provider of sample and assay technologies.

  • QIAGEN Completes Acquisition of Cellestis Limited.  // Worldwide Biotech;Oct2011, Vol. 23 Issue 10, p4 

    The article reports on the acquisition by Qiagen of Cellestis Limited. According to Peter M. Schiatz of Qiagen, the integration process will be started after completing the transaction. Information on the QuantiFERON® technology of Cellestis is presented. Qiagen is a holding company based in...

  • Qiagen to acquire Digene via cash and stock deal worth $1.6 billion. Johnson, Holland // Diagnostics & Imaging Week;6/7/2007, Vol. 10 Issue 23, p1 

    The article announces the plan of genetic testing equipment manufacturer Qiagen to acquire Digene. Qiagen will acquire Digene through a cash and stock deal amounting to $1.6 billion. Under the deal, shareholders of Qiagen will own 78 percent of the combine company, while Digene shareholders will...

  • Qiagen makes a grab for Cellestis.  // Australian Life Scientist;4/4/2011, p1 

    Cellestis board gives tick of approval to the deal which values the tuberculosis diagnostic company at $341.3 million.

  • Qiagen to buy Digene for $1.6B; Flextronics, Solectron to merge. Johnson, Holland // Medical Device Daily;6/5/2007, Vol. 11 Issue 107, p1 

    The article offers information on acquisition deals in the medical technology industry. Genetic testing equipment manufacturer Qiagen announced its plans to acquire Digene for $1.6 in cash and stock to expand into testing for cervical cancer and sexually transmitted diseases (STD). Flextronics...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics